Telsey Advisory Group analyst Dana Telsey reiterates Lululemon Athletica (NASDAQ:LULU) with a Outperform and maintains $425 price target.
Telsey Advisory maintained Lululemon Athletica (NASDAQ:LULU) $425 price target Read Post »
Wells Fargo analyst Aaron Rakers initiates coverage on Mobileye Global (NASDAQ:MBLY) with a Overweight rating and announces Price Target of $50.
Wells Fargo announced Mobileye Global (NASDAQ:MBLY) Price Target of $50 Read Post »
Mizuho analyst Vijay Rakesh maintains Mobileye Global (NASDAQ:MBLY) with a Buy and raises the price target from $39 to $43.
Mizuho raised Mobileye Global (NASDAQ:MBLY) price target from $39 to $43 Read Post »
RBC Capital analyst Tom Narayan reiterates Mobileye Global (NASDAQ:MBLY) with a Outperform and maintains $42 price target.
RBC Capital maintained Mobileye Global (NASDAQ:MBLY) $42 price target Read Post »
Wedbush Raises Salesforce (NYSE:CRM) Price Target to $230 From $220 to Reflect Improved Checks in Field, Maintains Outperform Rating.
Wedbush Raises Salesforce (NYSE:CRM) Price Target to $230 From $220 Read Post »
Citigroup analyst Tyler Radke maintains Salesforce (NYSE:CRM) with a Neutral and lowers the price target from $210 to $229.
Citigroup lowered Salesforce (NYSE:CRM) price target from $210 to $229 Read Post »
Barclays analyst Steve Valiquette maintains CVS Health (NYSE:CVS) with a Overweight and lowers the price target from $100 to $90.
Barclays lowered CVS Health (NYSE:CVS) price target from $100 to $90 Read Post »
Goldman Sachs analyst Nathan Rice maintains CVS Health (NYSE:CVS) with a Buy and lowers the price target from $100 to $88.
Goldman Sachs lowered CVS Health (NYSE:CVS) price target from $100 to $88 Read Post »
Raymond James analyst John Ransom maintains CVS Health (NYSE:CVS) with a Outperform and lowers the price target from $110 to $90.
Raymond James lowered CVS Health (NYSE:CVS) price target from $110 to $90 Read Post »
RBC Capital analyst Ben Hendrix reiterates CVS Health (NYSE:CVS) with a Outperform and maintains $102 price target.
RBC Capital maintained CVS Health (NYSE:CVS) $102 price target Read Post »
Piper Sandler analyst Jessica Tassan initiates coverage on CVS Health (NYSE:CVS) with a Overweight rating and announces Price Target of $85.
Piper Sandler announced CVS Health (NYSE:CVS) Price Target of $85 Read Post »
Snowflake (NYSE:SNOW) reported fiscal Q1 adjusted earnings of $0.15 per diluted share, compared with a breakeven a year earlier. Analysts polled by Capital IQ expected $0.05. Revenue for the quarter ended April 30 was $623.6 million, up from $422.4 million a year earlier. Analysts surveyed by Capital IQ expected $608.7 million. Looking ahead, the company expects product revenue of $620 million to $625 million for Q2 and $2.6 billion for fiscal 2024.